The SCAD-ALIGN trial, sponsored by Universitätsklinikum Hamburg-Eppendorf, aims to establish optimal antiplatelet therapy strategies for patients with spontaneous coronary artery dissection (SCAD), a condition predominantly affecting younger women. This trial is significant as it addresses a gap in current treatment protocols, which often apply general acute coronary syndrome guidelines that may not be suitable for SCAD patients. The results could lead to a paradigm shift in SCAD management, potentially influencing clinical guidelines and creating a new standard of care. Given the rarity of SCAD, successful outcomes may enhance the sponsor's reputation in cardiovascular research and open avenues for partnerships with other institutions and pharmaceutical companies interested in cardiovascular therapies. The market for antiplatelet therapies is substantial, and demonstrating the efficacy of a moderate treatment strategy could lead to a competitive advantage in this segment.